Polymyalgia rheumatica is an inflammatory disease that affects the shoulder, the pelvic
girdles, and the neck, usually in individuals older than 50 years. Increases in acute phase …

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease
affecting people older than 50 years and is 2–3 times more common in women. The most …

Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international
recommendations for PMR treatment are not currently available. In this paper, we report the …

Objectives To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and
polymyalgia rheumatica (PMR). Methods A systematic literature review was conducted to …

The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced
rapidly, resulting in a new understanding of these diseases. Fast-track strategies and …

Background Polymyalgia rheumatica is the second most common inflammatory rheumatic
disease of people> 50 years. Glucocorticoid therapy is highly effective, but many patients …

Giant cell arteritis (GCA) is the most common type of primary vasculitis in Western countries.
Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease …

Background Glucocorticoids are the cornerstone treatment of polymyalgia rheumatica (PMR)
but induce adverse events. Objectives To evaluate the efficacy and safety of first-line …

A systematic review and meta-analysis were conducted, according to the PRISMA
methodology, to summarize current evidence on the prevalence and predictors of long-term …

Objective Interleukin‐6 (IL‐6) is a pivotal cytokine in the pathogenesis of polymyalgia
rheumatica (PMR), yet the efficacy of IL‐6 blockade with tocilizumab (TCZ) for the treatment …